Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.

British journal of cancer - 25 Nov 2014

Sathe A, Guerth F, Cronauer M V, Heck M M, Thalgott M, Gschwend J E, Retz M, Nawroth R

Abstract excerpt

BACKGROUND: Alterations in the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway are frequent in urothelial bladder cancer (BLCA) and thus provide a potential target for novel therapeutic strategies. We investigated the efficacy of the AKT inhibitor MK-2206 in BLCA and the molecular determinants that predict therapy response. METHODS: Biochemical and functional effects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chickens
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Heterocyclic Compounds, 3-Ring

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25349966
DOI: 10.1038/bjc.2014.534
PMCID: PMC4260039

Genes

DUSP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.PMID 25349966Read ↗

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.Semantic proximity Read ↗

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.Semantic proximity Read ↗

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.Semantic proximity Read ↗

Molecular characterization of clear cell adenocarcinoma of the urinary bladder.Semantic proximity Read ↗

High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancerSemantic proximity Read ↗

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.Semantic proximity Read ↗

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progressionSemantic proximity Read ↗

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.Semantic proximity Read ↗

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Semantic proximity Read ↗

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).Semantic proximity Read ↗

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.